,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,companyOfficers,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,9 Deer Park Drive,Suite K-1,Monmouth Junction,NJ,08852,United States,609 452 9813,https://www.ayalapharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.","{'maxAge': 1, 'name': 'Mr. Kenneth A. Berlin J.D.', 'age': 58, 'title': 'Pres, CEO & Director', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,0.991,0.98,0.88,0.98,0.991,0.98,0.88,0.98,0.0,-1.2054794,2712,2712,5669,2457,2457,0.0,0.0,3000,1000,4257721,0.3568,1.95,20.37187,1.06172,0.79572845,0.0,0.0,USD,-1330753,0.0,2173674,4838320,80341,74009,1671062400,1673568000,0.0054,0.00017999999,0.16648,1.57,0.0135,4838320,0.211,4.170616,1672444800,1703980800,1688083200,-36012000,-2.21,-0.73,-6.367,0.033,-0.31782943,0.14113986,PNK,EQUITY,ADXS,ADXS,"Advaxis, Inc.","Ayala Pharmaceuticals, Inc.",1588944600,America/New_York,EDT,64ddc3fb-93a1-3fcf-bd77-6cb2e777109e,finmb_545964796,-14400000,0.88,4.0,4.0,4.0,4.0,1.0,strong_buy,1,7079000,1.481,-39980000,1542000,0.84,1.134,209000,152.825,0.013,-1.3877001,-3.92031,-21001000,-32805000,-0.763,0.0,0.0,-192.1531,USD,
1,9 Deer Park Drive,Suite K-1,Monmouth Junction,NJ,08852,United States,609 452 9813,https://www.ayalapharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.","{'maxAge': 1, 'name': 'Mr. Igor  Gitelman CPA, CPA, M.B.A., MBA', 'age': 46, 'title': 'Interim CFO & VP of Fin.', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,0.991,0.98,0.88,0.98,0.991,0.98,0.88,0.98,0.0,-1.2054794,2712,2712,5669,2457,2457,0.0,0.0,3000,1000,4257721,0.3568,1.95,20.37187,1.06172,0.79572845,0.0,0.0,USD,-1330753,0.0,2173674,4838320,80341,74009,1671062400,1673568000,0.0054,0.00017999999,0.16648,1.57,0.0135,4838320,0.211,4.170616,1672444800,1703980800,1688083200,-36012000,-2.21,-0.73,-6.367,0.033,-0.31782943,0.14113986,PNK,EQUITY,ADXS,ADXS,"Advaxis, Inc.","Ayala Pharmaceuticals, Inc.",1588944600,America/New_York,EDT,64ddc3fb-93a1-3fcf-bd77-6cb2e777109e,finmb_545964796,-14400000,0.88,4.0,4.0,4.0,4.0,1.0,strong_buy,1,7079000,1.481,-39980000,1542000,0.84,1.134,209000,152.825,0.013,-1.3877001,-3.92031,-21001000,-32805000,-0.763,0.0,0.0,-192.1531,USD,
2,9 Deer Park Drive,Suite K-1,Monmouth Junction,NJ,08852,United States,609 452 9813,https://www.ayalapharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.","{'maxAge': 1, 'name': 'Dr. Shmuel  Tuvia Ph.D.', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,0.991,0.98,0.88,0.98,0.991,0.98,0.88,0.98,0.0,-1.2054794,2712,2712,5669,2457,2457,0.0,0.0,3000,1000,4257721,0.3568,1.95,20.37187,1.06172,0.79572845,0.0,0.0,USD,-1330753,0.0,2173674,4838320,80341,74009,1671062400,1673568000,0.0054,0.00017999999,0.16648,1.57,0.0135,4838320,0.211,4.170616,1672444800,1703980800,1688083200,-36012000,-2.21,-0.73,-6.367,0.033,-0.31782943,0.14113986,PNK,EQUITY,ADXS,ADXS,"Advaxis, Inc.","Ayala Pharmaceuticals, Inc.",1588944600,America/New_York,EDT,64ddc3fb-93a1-3fcf-bd77-6cb2e777109e,finmb_545964796,-14400000,0.88,4.0,4.0,4.0,4.0,1.0,strong_buy,1,7079000,1.481,-39980000,1542000,0.84,1.134,209000,152.825,0.013,-1.3877001,-3.92031,-21001000,-32805000,-0.763,0.0,0.0,-192.1531,USD,
3,9 Deer Park Drive,Suite K-1,Monmouth Junction,NJ,08852,United States,609 452 9813,https://www.ayalapharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.","{'maxAge': 1, 'name': 'Ms. Irit Klipper Avni M.A.', 'title': 'VP of HR', 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,0.991,0.98,0.88,0.98,0.991,0.98,0.88,0.98,0.0,-1.2054794,2712,2712,5669,2457,2457,0.0,0.0,3000,1000,4257721,0.3568,1.95,20.37187,1.06172,0.79572845,0.0,0.0,USD,-1330753,0.0,2173674,4838320,80341,74009,1671062400,1673568000,0.0054,0.00017999999,0.16648,1.57,0.0135,4838320,0.211,4.170616,1672444800,1703980800,1688083200,-36012000,-2.21,-0.73,-6.367,0.033,-0.31782943,0.14113986,PNK,EQUITY,ADXS,ADXS,"Advaxis, Inc.","Ayala Pharmaceuticals, Inc.",1588944600,America/New_York,EDT,64ddc3fb-93a1-3fcf-bd77-6cb2e777109e,finmb_545964796,-14400000,0.88,4.0,4.0,4.0,4.0,1.0,strong_buy,1,7079000,1.481,-39980000,1542000,0.84,1.134,209000,152.825,0.013,-1.3877001,-3.92031,-21001000,-32805000,-0.763,0.0,0.0,-192.1531,USD,
4,9 Deer Park Drive,Suite K-1,Monmouth Junction,NJ,08852,United States,609 452 9813,https://www.ayalapharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.","{'maxAge': 1, 'name': 'Ms. Dana  Gelbaum M.B.A., M.Sc.', 'age': 48, 'title': 'GM & Chief Bus. Officer', 'yearBorn': 1974, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,0.991,0.98,0.88,0.98,0.991,0.98,0.88,0.98,0.0,-1.2054794,2712,2712,5669,2457,2457,0.0,0.0,3000,1000,4257721,0.3568,1.95,20.37187,1.06172,0.79572845,0.0,0.0,USD,-1330753,0.0,2173674,4838320,80341,74009,1671062400,1673568000,0.0054,0.00017999999,0.16648,1.57,0.0135,4838320,0.211,4.170616,1672444800,1703980800,1688083200,-36012000,-2.21,-0.73,-6.367,0.033,-0.31782943,0.14113986,PNK,EQUITY,ADXS,ADXS,"Advaxis, Inc.","Ayala Pharmaceuticals, Inc.",1588944600,America/New_York,EDT,64ddc3fb-93a1-3fcf-bd77-6cb2e777109e,finmb_545964796,-14400000,0.88,4.0,4.0,4.0,4.0,1.0,strong_buy,1,7079000,1.481,-39980000,1542000,0.84,1.134,209000,152.825,0.013,-1.3877001,-3.92031,-21001000,-32805000,-0.763,0.0,0.0,-192.1531,USD,
5,9 Deer Park Drive,Suite K-1,Monmouth Junction,NJ,08852,United States,609 452 9813,https://www.ayalapharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.","{'maxAge': 1, 'name': 'Dr. Andres A. Gutierrez M.D., Ph.D.', 'age': 61, 'title': 'Exec. VP & Chief Medical Officer', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,0.991,0.98,0.88,0.98,0.991,0.98,0.88,0.98,0.0,-1.2054794,2712,2712,5669,2457,2457,0.0,0.0,3000,1000,4257721,0.3568,1.95,20.37187,1.06172,0.79572845,0.0,0.0,USD,-1330753,0.0,2173674,4838320,80341,74009,1671062400,1673568000,0.0054,0.00017999999,0.16648,1.57,0.0135,4838320,0.211,4.170616,1672444800,1703980800,1688083200,-36012000,-2.21,-0.73,-6.367,0.033,-0.31782943,0.14113986,PNK,EQUITY,ADXS,ADXS,"Advaxis, Inc.","Ayala Pharmaceuticals, Inc.",1588944600,America/New_York,EDT,64ddc3fb-93a1-3fcf-bd77-6cb2e777109e,finmb_545964796,-14400000,0.88,4.0,4.0,4.0,4.0,1.0,strong_buy,1,7079000,1.481,-39980000,1542000,0.84,1.134,209000,152.825,0.013,-1.3877001,-3.92031,-21001000,-32805000,-0.763,0.0,0.0,-192.1531,USD,
